GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences

Rhea-AI Summary

GlycoMimetics, Inc. (Nasdaq: GLYC) announces participation in three virtual healthcare conferences in March 2021. Key events include:

• Cowen 41st Annual Health Care Conference: March 1-4, featuring Eric Feldman on a Leukemias Panel on March 3.
• H.C. Wainwright Global Life Sciences Conference: March 9-10, with CEO Rachel King presenting a corporate overview.
• 33rd Annual Virtual Roth Conference: March 15-17, where Rachel King will again present.

GlycoMimetics focuses on novel glycomimetic drugs for hematology-oncology.

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows:

Cowen 41st Annual Health Care Conference
March 1 – March 4, 2021
Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in Leukemias Panel
Wed, March 3, 2021, 11:40 a.m. – 12:40 p.m. (EST)
Access to the panel discussion is for registered attendees only.

H.C. Wainwright Global Life Sciences Conference
March 9 – 10, 2021
Rachel King, GlycoMimetics CEO, to present a corporate overview
The presentation will be available on-demand, beginning at 7 a.m. ET, March 9 through March 10. Access will be provided through the Company’s website (Investors section) and archived for 90 days.

33rd Annual Virtual Roth Conference
March 15 – 17, 2021
Rachel King, GlycoMimetics CEO, to present a corporate overview
Mon, March 15, 10:00 a.m. – 12:00 p.m. (EST) in Virtual 2 (Panel: Navigating Clinical Development in Rare Hematology & Inflammatory Disease). A link to the panel session will be available in the Investors section of the GlycoMimetics website.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005644/en/

FAQ

What conferences will GlycoMimetics participate in March 2021?

GlycoMimetics will participate in the Cowen 41st Annual Health Care Conference, H.C. Wainwright Global Life Sciences Conference, and the 33rd Annual Virtual Roth Conference.

When is the Cowen 41st Annual Health Care Conference?

The Cowen 41st Annual Health Care Conference is from March 1 to March 4, 2021.

Who will present at the H.C. Wainwright Global Life Sciences Conference?

Rachel King, the CEO of GlycoMimetics, will present a corporate overview at the conference on March 9-10, 2021.

What is the focus of GlycoMimetics?

GlycoMimetics focuses on developing novel glycomimetic drugs targeting hematology-oncology.

When will GlycoMimetics present at the 33rd Annual Virtual Roth Conference?

GlycoMimetics will present on March 15, 2021, from 10:00 a.m. to 12:00 p.m. EST.